Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Leases (2019 - 2022)

Aytu Biopharma has reported Current Leases over the past 4 years, most recently at $1.2 million for Q1 2022.

  • Quarterly Current Leases changed N/A to $1.2 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Mar 2022, changed N/A year-over-year, with the annual reading at $940000.0 for FY2021, 213.33% up from the prior year.
  • Current Leases was $1.2 million for Q1 2022 at Aytu Biopharma, up from $1.2 million in the prior quarter.
  • Over five years, Current Leases peaked at $1.2 million in Q1 2022 and troughed at $79362.0 in Q3 2019.
  • The 4-year median for Current Leases is $294619.0 (2020), against an average of $534907.6.
  • Year-over-year, Current Leases rose 21.16% in 2020 and then soared 1069.92% in 2021.
  • A 4-year view of Current Leases shows it stood at $82755.0 in 2019, then rose by 21.16% to $100263.0 in 2020, then soared by 1069.92% to $1.2 million in 2021, then rose by 2.56% to $1.2 million in 2022.
  • Per Business Quant, the three most recent readings for AYTU's Current Leases are $1.2 million (Q1 2022), $1.2 million (Q4 2021), and $1.1 million (Q3 2021).